Novavax Swings to Profit in Q4 2025 as Sales Surge; Shares Rally

Novavax Inc. (NVAX) reported a significant financial turnaround in its fourth-quarter 2025 results, shifting from previous losses to a net profit. The biotechnology firm's return to profitability was primarily driven by a substantial climb in sales revenue during the reporting period, exceeding previous performance metrics. Following the release of the quarterly and full-year financial data, shares of Novavax experienced an immediate upward trajectory in the market. This positive performance marks a critical milestone for the company as it strengthens its balance sheet and operational efficiency. Investors responded favorably to the news, viewing the sales growth as a strong catalyst for the company's long-term outlook in the pharmaceutical sector. The report highlights Novavax's successful efforts to stabilize its operations and capitalize on its product pipeline.